MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Marketable securities$238,000K Cash and cashequivalents$175,000K Accounts receivable, net$121,000K Prepaid expenses andother assets$68,000K Inventory$55,000K Total current assets$657,000K Property, plant, andequipment, net$239,000K Intangible assets, net$174,000K Marketable securities$121,000K Other assets$61,000K Goodwill$44,000K Total assets$1,296,000K Accumulated deficit-$4,717,000K Treasury stock, at cost,0.3 in 2026 and 0.2 in...$10,000K Total liabilities,noncontrolling interest and...$1,296,000K Total stockholders'equity (deficit)-$236,000K Additional paid-in capital$4,481,000K Deferred compensationobligation$10,000K Total liabilities$1,525,000K Noncontrolling interest$7,000K Liabilities for sales offuture royalties$1,128,000K Total currentliabilities$325,000K Other liabilities$42,000K Deferred tax liabilities$30,000K Accrued liabilities$194,000K Liabilities for sales offuture royalties$72,000K Accounts payable$42,000K Other liabilities$17,000K
Balance Sheet
source: myfinsight.com

Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx Pharmaceutical Inc. (RARE)